Pamplona

• A multi site clinical trial to evaluate the efficacy and safety of Qutenza® in subjects with post-surgical neuropathic pain Ended
  2024-514934-19-00 5 2021-11-08 Post-surgical neuropathic pain
• The BURAN Study of Buparlisib (AN2025) In Combination with Paclitaxel Compared to Paclitaxel Alone, in Patients with Recurrent or Metastatic … Ended
  2024-517251-12-00 5 2021-11-02 Recurrent or metastatic head and neck squamous cell carcinoma
• A study to learn if bepranemab is safe and works in people with early stages of Alzheimer’s Disease Ended
  2023-506170-12-00 4 2021-10-18 Alzheimer’s Disease
• A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Plac … Ended
  2024-511066-36-00 5 2021-10-13 Light Chain (AL) Amyloidosis
• Phase III Study of Efficacy and Safety of Secukinumab Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patients With Gia … Ended
  2024-510744-31-00 5 2021-10-06 Giant cell arteritis (GCA)
• A study to assess the safety and efficacy of AZD7789 in participants with advanced or metastatic solid cancer Ended
  2022-502774-17-00 7 2021-10-04 Advanced or metastatic gastric and gastro-esophageal junction (GEJ) ad
• A Randomized, Open-Label Trial to Compare Tisotumab Vedotin to Investigator's Choice Chemotherapy in Patients with Cervical Cancer Ended
  2023-503813-31-01 5 2021-09-17 Second- or Third-Line Recurrent or Metastatic Cervical Cancer
• First-in-Human Study of RLY-4008 in Patients With ICC and Other Advanced Solid Tumors Ended
  2024-512622-29-00 7 2021-09-10 Cholangiocarcinoma (CCA) and Other Advanced Solid Tumors
• A study of PRS-344/S095012 (PD-L1x4-1BB bispecific antibody) in patients with solid tumors Ended
  2023-510046-25-00 7 2021-09-02 Soild Tumors
• Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) Ended
  2024-511728-15-00 7 2021-08-26 Solid tumors
• A Phase 2 Study of ALX148 in Combination with Pembrolizumab in Patients with Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03) Ended
  2023-508340-22-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Phase 2 study of ALX148 in Combination With Pembrolizumab and Chemotherapy in Patients with Advanced Head and Neck Squamous Cell Carcinoma … Ended
  2023-508342-17-00 4 2021-08-11 metastatic or unresectable, recurrent HNSCC
• A Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer Ended
  2024-511158-36-00 9 2021-08-05 Metastatic colorectal cancer
• A Multicenter, Open-Label, Phase I/II Study of EOS884448 in combination with standard of care and/or investigational therapies in participan … Ended
  2024-512227-36-00 9 2021-07-28 Advanced solid tumors
• Lighthouse II study Ended
  2024-517054-94-00 5 2021-07-05 AMYOTROPHIC LATERAL SCLEROSIS
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cy … Ended
  2023-507497-40-00 1 2021-05-31 Diffuse large B-cell lymphoma (DLBCL), Grade 3B follicular lymphoma, H
• Non-inferiority study of GSK3511294 (depemokimab) compared with mepolizumab or benralizumab in participants with severe asthma with an eosin … Ended
  2023-510230-84-00 5 2021-05-28 Severe asthma with an eosinophilic phenotype
• A randomized, 2-arm, open-label, phase II study of abemaciclib combined with endocrine therapy (letrozole or fulvestrant) with or without a … Ended
  2023-509591-42-00 4 2021-05-04 HR-positive/HER2-negative breast cancer
• Polatuzumab vedotin plus rituximab, ifosfamide, carboplatin and etoposide (Pola-R-ICE) versus R-ICE alone in second line treatment of diffus … Ended
  2023-508259-38-00 5 2021-04-29 Adult patients with relapsed or primary refractory DLBCL
• An Open-label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination with Atezolizumab in Patients with Locally Ad … Ended
  2023-506285-31-00 1 2021-04-21 Locally Advanced or Metastatic Solid Tumors
• A Study to Evaluate Effects of RO7121661 and RO7247669 Compared With Nivolumab in Advanced or Metastatic Squamous Cell Carcinoma of the Esop … Ended
  2024-511403-41-00 4 2021-04-14 Advanced or metastatic squamous cell carcinoma of the esophagus
• GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies Ended
  2023-507086-26-00 7 2021-03-09 Relapsed or Refractory Multiple Myeloma (RRMM) Diffuse Large B Cell L
• Phase I/II trial of S65487 plus azacitidine in acute myeloid leukemia Ended
  2023-510051-27-00 7 2021-02-25 Acute Myeloid Leukemia (AML)
• A Phase 1, First-in-Human, Dose Escalation Study of the JNJ-75348780 Bispecific Antibody Targeting CD3 and CD22 in Participants with NHL and … Ended
  2023-504403-92-00 1 2021-02-15 Relapsed/refractory B-cell Non-Hodgkin Lymphoma (NHL) and Chronic Lymp

Showing 745–768 of 821 trials